Elahere is a type of targeted therapy called an antibody-drug conjugate. This antibody-drug conjugate is made up of an antibody that is attached to a cancer medicine. Elahere is used to treat a ...

AbbVie ABBV continues to build momentum with its oncology franchise, with the recent FDA approval for Emrelis. This ...

ELAHERE was approved under FDA's accelerated approval program based on objective response rate (ORR) and duration of response (DOR) data from the pivotal SORAYA trial. Continued approval may be ...

Elahere (mirvetuximab soravtansine-gynx*) is a prescription drug used to treat certain types of cancer, including ovarian cancer. Elahere comes as a liquid solution that’s given as an ...

Final data analysis from Phase 3 MIRASOL trial after 30.5-month median follow-up demonstrated 32% reduction in risk of death with ELAHERE compared to chemotherapy in folate receptor alpha (FRα ...

Elahere (mirvetuximab soravtansine-gynx) is a brand-name injection that’s prescribed for certain types of cancer. As with other drugs, Elahere can cause side effects, such as eye problems ...

ImmunoGen's Elahere (mirvetuximab soravtansine-gynx) has shown positive results in a confirmatory trial for platinum-resistant ovarian cancer, boosting the company's stock by over 130%.

Elahere (mirvetuximab soravtansine-gynx) is a brand-name injection that’s prescribed for certain types of cancer. Elahere has interactions with some other drugs. Examples include certain ...

ELAHERE® (mirvetuximab soravtansine-gynx) was granted full FDA approval in the United States in March 2024. Marketing authorization submissions for mirvetuximab soravtansine are under review ...

Data Further Support Potential of ELAHERE to Become the New Standard of Care for Patients with FRα-Positive Platinum-Resistant Ovarian Cancer MIRASOL Results to be Highlighted in Late-Breaking Oral ...

If approved, this will be the first regulatory approval for Elahere in the EU. ABBV Stock Performance Year to date, AbbVie’s shares have moved up 24.9% compared with the industry’s 23.5% rise.